News

Equity Financing

MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an...

read more

Innovation Foundation Grant

MinervaX announces that the company has been awarded a grant worth DKK 4.5 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for...

read more

Initiation of Phase I Part B

MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy...

read more

Equity and Loan Financing

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. MinervaX, a privately held Danish...

read more

FP7 Grant

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. NeoStrep, a consortium consisting...

read more